Press Releases
Jun 8, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology...

May 19, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced updated results from two clinical trials examining PADCEV®...

May 17, 2021

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology...

EXPLORE ALL US PRESS RELEASES

Articles
May 27, 2021

Astellas is at an inflection point in our evolution, facing opportunities presented by our growing pipeline, but amidst a rapidly changing environment that is transforming the ways every segment...

Jun 15, 2021

Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

Jun 3, 2021

Astellas Pharma Inc. announced changes in its Global Commercial Leadership Team reporting to Chief Commercial Officer Yukio Matsui aligned with the focuses for the new Corporate Strategic Plan 2021 (CSP2021).

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products